While the prevalence of hypertension is clearly increased among the overweight persons, the pathophysiological mechanisms underlying this frequent association of obesity and hypertension are still poorly understood. The expansion of extracellular volume, inducing hypervolaemia and increased cardiac output, represents the characteristic haemodynamic feature of the obesity-related hypertension. The maintenance of hypervolemia in the face of elevated blood pressure, indicates a resetting of pressor natriuresis toward higher blood pressure. The development of hypertension also indicates an increase in peripheral vascular resistance, thus the lack of physiological adaptation of peripheral resistance to increased cardiac output. The mechanisms underlying these changes in renal function and vascular reactivity can no longer be attributed to hyperinsulinaemia as such, but might be related to insulin resistance responsible for the enhancement in pressor activity of noradrenaline and angiotensin II. This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in vascular smooth muscle cells. The role of increased neuropeptide Y (NPY) activity, may also be involved. As to enhancement of tubular sodium reabsorption, it could be related to histological changes within the renal medulla, leading to compression of tubules and vasa recta, hence a more ef®cient sodium reabsorption. As to the therapeutic approach, the low-energy sodium-restricted diet associated with increased physical activity, represents the cornerstones of treatment for the obesity-related hypertension. If this approach fails, the pharmacological treatment becomes necessary, and the use of the converting enzyme inhibitors seems to be the most appropriate choice of drug therapy for hypertensive obese patients.
Introduction
While obesity and hypertension are frequently associated, the pathophysiological link between these morbid conditions is not entirely clear, despite a considerable number of investigations conducted to unravel the mechanisms by which overweight and obesity elevate blood pressure (see reference 1 ± 7). The frequency of hypertension in obese individuals may however vary according to gender, ethnicity and age. 1 Indeed, this association is stronger in women than in men, and in subjects of Caucasian than of African origin. 1, 3 While the prevalence of hypertension, as well as of obesity, increases with age, the overweight-related relative risk to develop hypertension seems to be higher in younger subjects. 3 From the haemodynamic standpoint, obesity-associated hypertension is characterised essentially by increased intravascular volume, 2, 6, 8 whereas the peripheral vascular resistance is`abnormally normal' (at least from the physiological point of view) or only slightly elevated. 1, 2 The volume expansion appears therefore as a key factor determining the tendency toward hypertension in obese subjects. This implies that the primary defect leading to increased intravascular volume and cardiac output, and ultimately to hypertension, should consist of some abnormality in kidney function responsible for a shift in pressor natriuresis to higher blood pressure values. 2, 9 According to this view, obesity-related hypertension can be seen as a haemodynamic adaptation allowing the maintenance of sodium balance, despite the resetting of pressor natriuresis. 1, 2, 6 As with many other forms of hypertension, the obesity-induced hypertension should therefore be considered as`salt-sensitive', 1, 6, 9, 10 and the understanding of mechanisms responsible for the resetting of pressor natriuresis inducing a permanent expansion of extracellular¯uid and blood volume is essential for the elucidation of the pathophysiological link between overweight and hypertension. While it is possible that some common mechanisms may affect both the renal sodium handling and the peripheral vascular resistance, the pathophysiology of the abnormal tubular sodium retention and the lack of a normal adaptation of the peripheral vascular resistance to increased cardiac output, will be discussed separately.
The abnormality of renal function leading to hypervolaemia in obese hypertensive subjects
As already mentioned, the maintenance of the expansion of extracellular volume in the face of elevated blood pressure (which in physiological conditions induces an increase in renal sodium excretion allowing the normalisation of blood volume) obviously implies a resetting of pressor natriuresis. 2, 6, 7, 9, 11 Since the glomerular ®ltration rate, as well as renal blood¯ow, are both increased rather than decreased in obese hypertensive man or dog, 1, 2, 9 it is evident that the mechanisms underlying the shift in pressor natriuresis consist of an enhancement of the tubular sodium reabsorption. 7, 99 Several studies suggest that the increased sodium reabsorption in obese hypertensives occurs somewhere beyond the proximal tubule, probably in the thin ascending limb of Henle's loop (see references 1,6 and 9) . This leads to decreased sodium delivery to macula densa, hence increased renin release and angiotensin II generation. According to Hall, 2 the inability to adequately suppress angiotensin II formation in the face of hypervolaemia or when salt intake is raised, represents a key factor in determining the salt sensitivity of the obesityrelated hypertension. However, the importance of the increased activity of the renin-angiotensin-aldosterone system as a factor promoting the obesityrelated hypertension may be questioned, as according to some studies the plasma renin activity and aldosterone levels are either unchanged or even inversely related to body weight and blood pressure. 6, 8 Several mechanisms have been proposed to explain the inability of the kidney to excrete the increased amount of sodium in response to the rise in blood pressure, thus the mechanisms underlying the shift in pressure natriuresis in obese hypertensives. The direct role for hyperinsulinaemia as a factor responsible for the development of hypertension in obese subjects through a stimulatory in¯uence of insulin on renal sodium reabsorption has been suggested by some investigators. 5, 10, 12, 13 According to others, 1,7,9,14 it seems unlikely, however, that hyperinsulinaemia represents a physiological link between obesity and hypertension. Indeed, no correlation has been found between insulin levels and blood pressure in a large epidemiological survey conducted in several European countries, 15 and blood pressure and insulinaemia are unrelated in genetically obese Pima Indians. 16 Moreover, the studies conducted on dogs indicate that a direct insulin infusion into the renal artery does not modify renal sodium handling or haemodynamics, 17 and that a chronic insulin infusion is without any effect on sodium balance or blood pressure. 2, 14, 18 Since numerous epidemiological and clinical studies have evidenced the frequent association between hypertension and insulin resistance (for references see Refs. 1,2,7,19), it is generally believed that the decreased insulin sensitivity is a key pathophysiological factor promoting hypertension not only by increasing the peripheral vascular resistance, but also by inducing an abnormal renal sodium handling. 1, 5, 11, 20 The mechanism by which the state of insulin resistance might promote renal sodium retension has never been demonstrated 7, 9 and it cannot be excluded that insulin resistance and hypertension simply coexist in overweight subjects, without any causal relationship. This opinion, already expressed by O'Hare 10 years ago 21 is shared by some more recent reports. 2, 7, 9, 14, 18 According to others, insulin resistance may be a predisposing but not suf®cient factor in the pathogenesis of hypertension, and it has been suggested that only in genetically predisposed individuals may insulin resistance have an impact on renal tubular function, inducing a resetting of pressor natriuresis. 11, 22 Indeed, no association between insulin resistance and blood pressure has been found in some ethnic groups genetically predisposed to obesity and insulin resistance, 16 hence the suggestion that the genes responsible for insulin resistance and for salt sensitivity may be distinct. 22 Since insulin has no direct effect on renal tubular function, it seems unlikely that the tubular sodium reabsorption could be directly modi®ed by changes in insulin sensitivity. The insulin resistance may in¯uence, however, the renal sodium handling indirectly, through other mechanisms in¯uencing renal haemodynamics, namely the medullary vasoconstriction responsible for enhanced tubular sodium reabsorption in the ascending limb of Henle's loop. 1, 2, 7, 14 As suggested by Rocchini, 20 both insulin resistance and increased sympathetic nervous system activity correlate with increased sodium sensitivity and hypertension, and noradrenaline pressor activity is augmented in obese insulin resistant subjects. 19, 23 It has been therefore suggested that increased activity of the sympathetic nervous system, as well as the reninangiotensin system, may underline the interrelationship between salt sensitivity and insulin resistance. 2, 24 It is also possible, but not proven, that insulin resistance may induce the vasoconstriction of the deep medullary blood vessels leading to increased sodium reabsorption, through the inhibition of endothelial nitric oxide (NO) release. 1, 7 Indeed, it has been recently reported that intrarenal NO perfusion increases diuresis and natriuresis, and that NO can even directly inhibit sodium reabsorption by the cortical collecting duct. 25 Thus, it is possible that a chronic inhibition of NO synthesis may reduce sodium excretion and promote the hypertensive shift of pressor natriuresis in the insulin-resistant subjects. 25, 26 The possibility that increased neuropeptide Y (NPY) release within the kidney, as a consequence of insulin resistance or increased noradrenergic activity, may alter renal haemodynamics and sodium reabsorption, remains purely 27 According to the observation reported by Hall and co-workers, 2,9,14,18 the obesity-related changes in physical forces within the deep medullary portion of the kidney, rather than a primary haemodynamic or tubular mechanism, are responsible for the hypertensive resetting of pressor natriuresis. The latter effect is considered by these authors as secondary to the obesity-associated interstitial cell proliferation and increased deposition of noncellular matrix within the renal medulla, causing an increase in hydrostatic pressure responsible for the compression of tubules and vasa recta. This should obviously lead to an enhancement of sodium reabsorption by the thin ascending loop of Henle. As a consequence of these changes, the delivery of sodium to the macula densa should be reduced, hence increased activity of the renin-angiotensin system which seems to be involved in the resetting of pressor natriuresis.
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Whatever the mechanism involved, it is clear that a shift in renal pressor natriuresis toward a higher blood pressure and renal sodium excretion relationship, represents a major mechanism responsible for the chronic expansion of extracellular¯uids resulting in hypervolaemia, increased cardiac output and arterial hypertension. It is noteworthy that even a moderate loss of weight induced in obese subjects by the restriction of energy intake is followed by a fall in blood pressure due to the reduction of intravascular volume as a result of an increased urinary sodium excretion, which occurs despite reduced blood pressure values. 20, 28 This is in keeping with the concept that hypervolaemia represents a major haemodynamic feature of the obesity-related hypertension. 6 ± 10 The mechanisms involved in the increased peripheral vascular resistance Since all forms of hypertension obviously result from an imbalance between cardiac output and peripheral vascular resistance, and since the blood volume and cardiac output are increased in hypertensive obese subjects, it is evident that the maintenance of elevated blood pressure re¯ects, in these subjects, the inability of vascular resistance to adequately decrease, thus to adapt physiologically to the increased preload. The peripheral vascular resistance is therefore`abnormally normal' or even increased in obese subjects suffering from hypertension. 1,2,5 ± 7 The mechanism of this abnormally elevated vascular reactivity remains unclear and probably involves several factors which may be interrelated. Several investigators pointed out that the sympathetic nervous system activity is increased in obese hypertensive subjects, 4, 5, 14, 19, 23 but others reported that circulating levels and urinary excretion of noradrenaline are within the normal range in obese hypertensives and unrelated to blood pressure values. 8, 13 The latter observations do not exclude, however, the possible role of noradrenaline as a factor increasing the peripheral vascular resistance, since it has been reported that the noradrenalineinduced peripheral vasoconstriction might be enhanced in obese hypertensive subjects with severe insulin resistance. 1, 23 Insulin as such can no longer be considered as a factor promoting hypertension. Indeed, when perfused in normal man or dog, insulin lowers blood pressure, increases the peripheral (muscular) blood¯ow, decreases peripheral vascular resistance and lowers the pressor effect of noradrenaline and angiotensin II. 2, 14, 18 Interestingly, the vasodilating effect of insulin seems to be related to its effect on peripheral glucose uptake, 29 and it may result not only from reduced sensitivity to pressor agents, but also from the stimulatory effect of insulin on NO release by vascular endothelium. 30 These multiple effects of insulin obviously explain the hypotensive effect of insulin in normal man and suggest that the lack of these physiological actions of insulin, which characterises the state of insulin resistance, may be one among the mechanisms which promote the development of hypertension in obese subjects. 1, 7, 12, 14, 19, 20 As to the excessive vascular reactivity to pressor agents frequently observed in obese insulin-resistant hypertensive subjects, 1, 23 it may re¯ect the excessive cytoplasmic sodium and calcium accumulation within the smooth muscles of arterial walls. 1, 5, 6, 19 The increased peripheral vascular resistance is, however, not necessarily induced by the state of insulin resistance. As already mentioned, no increase in the prevalence of hypertension occurs in Pima Indians, despite the frequent association of obesity and insulin resistance. 16 Moreover, it has been reported that in obese subjects with a severe impairment of the insulin-mediated glucose disposal, the blood pressure lowering haemodynamic responses to insulin were not altered. 31 It cannot be excluded, therefore, that there is no direct pathophysiological link between insulin resistance and hypertension, 7, 18, 21, 22 , but that some common mechanism may promote hypertension and inhibit the metabolic response to insulin. The recent observation that angiotensin II may impair the cellular response to insulin, 32 is in keeping with such a concept. Thus, the activation of the renin-angiotensin system, which characterises obesity-related hypertension, may therefore lead to reduced metabolic and vascular effects of insulin and explain the frequent association of insulin resistance and hypertension. It is also possible that elevated circulating NPY levels may enhance vascular reactivity in obese subjects, since NPY is a potent vasoconstrictor reducing the peripheral blood¯ow. 27 Even if increased vascular resistance contributes to hypertension in obese subjects, it is of interest to note that the hypotensive effect of weight loss induced by an Obesity and hypertension J Kolanowski et al energy-restricted diet, is due essentially to a decrease in blood volume, while the peripheral vascular resistance remains apparently unchanged. 28 
Therapeutic conclusions
It is evident that long-term dietary treatment, consisting of a moderate restriction of energy and salt intake, represents the most effective and safe treatment for obesity-associated hypertension. 1, 6, 7 The hypotensive effect of the diet is reinforced by the concomitant increase in physical activity, which may improve the blood pressure control even if body weight remains unchanged. 1 The low energy diet-induced fall in blood pressure, which may be observed irrespective of sodium intake, 4 results initially from increased natriuresis allowing the reduction in blood volume. 20, 28 After several weeks of diet, it also occurs the reduction of the peripheral vascular resistance due to the inhibition of sympathetic activity and of the reninangiotensin system. 5, 33, 34 In addition to the reduction in salt sensitivity and noradrenergic activity, the weight reduction and increased physical activity clearly improve the insulin sensitivity, which may alleviate the mechanisms responsible for the development of hypertension in insulin resistant hypertensive obese subjects. 1, 7 It is noteworthy that these bene®cial effects already occur after a partial, moderate loss of weight and are in general associated with the improvement of other cardiovascular risk factors.
If the dietary treatment is not really applied by the patients, or does not allow the normalisation of blood pressure, the pharmacological treatment of hypertension becomes necessary. Among different types of hypotensive agents, the angiotensin converting enzyme inhibitors are considered as the most appropriate. 1, 6, 7 Aside for the bene®cial effect of the inhibition of angiotensin II formation on pressor natriuresis, 2 this treatment promotes peripheral vasodilation, thus a reduction in peripheral vascular resistance. In addition, the inhibition of angiotensin II generation is followed by a signi®cant improvement in insulin sensitivity, 35 ± 37 while b-blockers, such as atenolol, can even worsen the insulin resistance. 36 The alpha-1 receptor and calcium entry blockers are ef®-cient in lowering blood pressure in the hypertensive obese, without making the lipid and carbohydrate metabolic abnormalities worse. 1, 6, 7 Some reports even suggested that these agents may improve insulin sensitivity. 6, 37 The recently introduced selective blockers of angiotensin II subtype 1 receptor, may also be used for treatment of the obesity-related hypertension, but the effect of these agents on insulin sensitivity awaits elucidation. Indeed, while some clinical observations suggest that losartan, a speci®c antagonist of subtype 1 angiotensin II receptors, lowers blood pressure, improves insulin sensitivity and decreases sympathetic nervous system activity, 38 the same agent was unable to prevent the inhibitory effect of angiotensin II on insulin action in aortic smooth muscle cells. 32 While b-blockers, such as metoprolol, may have a bene®cial effect on blood pressure control in obese hypertensives, these agents may adversely affect blood lipids by raising triglyceride and lowering HDL-cholesterol levels. 6 These agents may also make insulin resistance worse, especially when associated with thiazide diuretics. 1, 7, 36 
